First human test of potential IPF treatment shows early safety profile
NCT ID NCT03422068
Summary
This early-stage study tested the safety and how the body processes a new oral medication called BI 1015550 in people with idiopathic pulmonary fibrosis (IPF). It involved 15 patients who were not taking other standard IPF medications. The main goal was to see what side effects occurred and to measure how much of the drug stayed in the bloodstream over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus Medisch Centrum
Rotterdam, 3015 CE, Netherlands
-
Fraunhofer ITEM
Hanover, 30625, Germany
-
HYKS Keuhkosairauksien tutkimusyksikkö
Helsinki, 00290, Finland
-
Hospital de Bellvitge
L'Hospitalet de Llobregat, 08907, Spain
-
Odense University Hospital
Odense, 5000 C, Denmark
-
Poli Univ A. Gemelli
Roma, 00168, Italy
-
Royal Brompton Hospital
London, SW3 6NP, United Kingdom
-
Southampton General Hospital
Southampton, SO16 6YD, United Kingdom
-
St. Antonius ziekenhuis, locatie Nieuwegein
Nieuwegein, 3435 CM, Netherlands
-
TYKS
Turku, 20520, Finland
-
Universitätsklinikum Heidelberg
Heidelberg, 69126, Germany
Conditions
Explore the condition pages connected to this study.